LEON appoints Dr Setu Kasera as CSO

Leon-nanodrugs GmbH (LEON) has announced the appointment of Dr Setu Kasera as its new chief scientific officer (CSO) effective 15 June 2023.
Previously, Kasera has acted as LEON’s head of Science and Engineering; having held this role since October 2022 she has worked to increase the development of the company’s devices and put its proprietary technology to practice. Kasera has vast expertise in nanotechnology from her R&D work at the University of Cambridge where she received her MPhil and PhD, as well as independent research projects, alongside experience within the pharma industry and chemistry, manufacturing and controls (CMC).
Kasera succeeds Dr Frank Stieneker, who will continue to support LEON as an exclusive advisor.
Dr Robert Becker, chairman of the LEON Supervisory Board, commented: “Setu has hands-on experience in nanotechnology, and has already taken a leading role in bringing our technology to application. As CSO, Setu will continue the development of LEON’s devices to completion and tailor the product offering to LEON’s target groups. I also express my sincere gratitude to Frank Stieneker, who has been a vital driver in the development of LEON’s ingenious reactor technology and who has significantly contributed to LEON’s strategic outline. We are very pleased that we will continue to work with him and can count on his expertise and support in his new advisory role.”
Stieneker added: “Conceiving LEON’s technology and, together with the team, putting theory to practice by realizing the FR-JET reactor, which now serves as a core piece of LEON’s manufacturing devices, was a truly rewarding experience. As I will continue to advise and support LEON in the future, I look forward to seeing the potential of LEON’s devices unfold and revolutionise the manufacturing of nanomedicines and ultimately, enhance access for patients.”
Commenting on her new role, Kasera said: “Managing the implementation of the FR-JET technology and seeing its performance first-hand, I can only underline that LEON’s encapsulation devices are certain to cause a disruptive impact in the R&D and GMP-manufacturing of nanomedicines. I take great pleasure in continuing to direct the development of LEON’s devices and in facilitating the adaptation of this advanced technology to the processes of our business partners and clients, finally accelerating the timeline from drug development to patient.”